These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Pitfalls in intravesical immunotherapy of superficial carcinoma of the gallbladder with BCG vaccine]. Pacík D; Vít V; Turjanica M Rozhl Chir; 1997 Jan; 76(1):3-5. PubMed ID: 9182342 [TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guérin immunotherapy. Techniques and results. Brosman SA Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239 [TBL] [Abstract][Full Text] [Related]
5. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer. Sosnowski JT Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653 [No Abstract] [Full Text] [Related]
6. BCG in bladder cancer--a warning. Nicol D Aust N Z J Med; 1995 Aug; 25(4):275-7. PubMed ID: 8540864 [No Abstract] [Full Text] [Related]
7. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst). Barreto L; Csizer Z; Sparkes JD Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667 [TBL] [Abstract][Full Text] [Related]
8. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Lamm DL Oncology (Williston Park); 1995 Oct; 9(10):947-52, 955, discussion 955-65. PubMed ID: 8573479 [TBL] [Abstract][Full Text] [Related]
9. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer. Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019 [TBL] [Abstract][Full Text] [Related]
10. BCG for bladder cancer. Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783 [No Abstract] [Full Text] [Related]
11. [Intravesical BCG as a treatment for superficial and in situ transitional cell carcinoma of the bladder]. Schmidt AC; de Kock ML; de Klerk DP S Afr Med J; 1990 Apr; 77(7):354-7. PubMed ID: 2321105 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant immunotherapy in superficial bladder cancer. Morales A Natl Cancer Inst Monogr; 1978 Dec; (49):315-9. PubMed ID: 748787 [TBL] [Abstract][Full Text] [Related]
13. Arthritis and iritis after BCG therapy for bladder cancer. Price GE J Rheumatol; 1994 Mar; 21(3):564-5. PubMed ID: 8006904 [TBL] [Abstract][Full Text] [Related]
14. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy. Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162 [No Abstract] [Full Text] [Related]
15. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer. Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496 [TBL] [Abstract][Full Text] [Related]
16. [Severe self-limiting hypersensitivity reaction after immunotherapy with intravesical BCG]. Estelles Piera FJ; Campayo A; Valls Ferrer JM; Lacruz J; Blanes Julia FM; López Aldeguer J; Bonora Tamarit V An Med Interna; 1994 Oct; 11(10):503-5. PubMed ID: 7865660 [TBL] [Abstract][Full Text] [Related]